Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT)

DOUBEK, Michael, Jan MUŽÍK, Tomáš SZOTKOWSKI, Vladimír KOZA, Petr CETKOVSKÝ, Tomáš KOZÁK, Pavel ŽÁK, Jaroslava VOGLOVÁ, Soňa ŠTRUNCOVÁ, Ladislav DUŠEK and Karel INDRÁK. Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT). Neoplasma. Bratislava, vol. 54, No 1, p. 89-94. ISSN 0028-2685. 2007.

Basic information

• Original name: Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT)
• Name in Czech: Je FLT3 tandemová duplikace významným indikátorem pro alogenní transplantaci u akutní myeloidní leukémie? Analýza pacientů registru akutních leukémií (ALERT)
• Name (in English): Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT)
• Authors: DOUBEK, Michael (203 Czech Republic, guarantor), Jan MUŽÍK (203 Czech Republic), Tomáš SZOTKOWSKI (203 Czech Republic), Vladimír KOZA (203 Czech Republic), Petr CETKOVSKÝ (203 Czech Republic), Tomáš KOZÁK (203 Czech Republic), Pavel ŽÁK (203 Czech Republic), Jaroslava VOGLOVÁ (203 Czech Republic), Soňa ŠTRUNCOVÁ (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic) and Karel INDRÁK (203 Czech Republic).
• Edition: Neoplasma, Bratislava, 2007, 0028-2685.

Other information

• Original language: Czech
• Type of outcome: Article in a journal
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: Czech Republic
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 1.208
• RIV identification code: RIV/00216224:14110/07:00032737
• Organization unit: Faculty of Medicine
• UT WoS: 000246073100014
• Keywords in English: HUMAN HEMATOLOGIC MALIGNANCIES; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; FLT3-ACTIVATING MUTATIONS; PROGNOSTIC-SIGNIFICANCE; RISK GROUP; 12 TRIALS; AML 10; CYTOGENETICS; EXPRESSION
• Tags: 12 TRIALS, ACUTE MYELOGENOUS LEUKEMIA, ACUTE PROMYELOCYTIC LEUKEMIA, AML 10, cytogenetics, Expression, FLT3-ACTIVATING MUTATIONS, HUMAN HEMATOLOGIC MALIGNANCIES, PROGNOSTIC-SIGNIFICANCE, RISK GROUP

Abstract

AML patients, we performed an analysis of all patients with FLT3 mutations registered in the Czech Acute Leukemia Clinical Register (ALERT) from 2003 till the end of 2005. Within the mentioned period 170 patients with AML of median age 56 years (23-77) were investigated for FLT3 mutation, within them 36 cases (21 %) with FLT3 mutations (32 FLT3 ITD and 4 FLT3 D835) were found.Out of FLT3 ITD positive patients 13 had allogeneic transplantation, 20 patients with mutations of FLT3 were treated with chemotherapy without transplantation. Results of the treatment of these patients were compared with the results of the group of patients without FLT3 mutation, which was according to other characteristics identical with the group of patients with FLT3 mutations (n=134). Median overall survival (OS) was significantly shorter for patients with FLT3 ITD (34.8 weeks) than for those without FLT3 mutations (67.7 weeks; P=0.028). Median OS of patients with FLT3 ITD who had allogeneic transplantation was 42.5 weeks; median OS of patients with FLT3 ITD treated only with chemotherapy was 29.6 weeks (P=0.362). After allogeneic transplantation, median OS of FLT3 mutations negative patients was similar to FLT3 ITD positive patients (46.7 versus 42.5 weeks; P=0.443). Our results suggest that at present there is no strong evidence that FLT3 status alone should influence the decision to proceed to allogeneic transplantation in AML patients.

Abstract (in English)

AML patients, we performed an analysis of all patients with FLT3 mutations registered in the Czech Acute Leukemia Clinical Register (ALERT) from 2003 till the end of 2005. Within the mentioned period 170 patients with AML of median age 56 years (23-77) were investigated for FLT3 mutation, within them 36 cases (21 %) with FLT3 mutations (32 FLT3 ITD and 4 FLT3 D835) were found.Out of FLT3 ITD positive patients 13 had allogeneic transplantation, 20 patients with mutations of FLT3 were treated with chemotherapy without transplantation. Results of the treatment of these patients were compared with the results of the group of patients without FLT3 mutation, which was according to other characteristics identical with the group of patients with FLT3 mutations (n=134). Median overall survival (OS) was significantly shorter for patients with FLT3 ITD (34.8 weeks) than for those without FLT3 mutations (67.7 weeks; P=0.028). Median OS of patients with FLT3 ITD who had allogeneic transplantation was 42.5 weeks; median OS of patients with FLT3 ITD treated only with chemotherapy was 29.6 weeks (P=0.362). After allogeneic transplantation, median OS of FLT3 mutations negative patients was similar to FLT3 ITD positive patients (46.7 versus 42.5 weeks; P=0.443). Our results suggest that at present there is no strong evidence that FLT3 status alone should influence the decision to proceed to allogeneic transplantation in AML patients.

Links

• MSM0021622412, plan (intention): Name: Interakce mezi chemickými látkami, prostředím a biologickými systémy a jejich důsledky na globální, regionální a lokální úrovni (INCHEMBIOL) (Acronym: INCHEMBIOL)

Investor: Ministry of Education, Youth and Sports of the CR, Interactions among the chemicals, environment and biological systems and their consequences on the global, regional and local scales (INCHEMBIOL)